that's fair enough - this is quite different from normal cancer therapies where you could be dosed continuously. The results from an untreated person with a CAR-T-treated person will be different from a treated person so its ideal that they don't just change doses unless for managing adverse events.
Unfortunately, it is the case for many phase 1 patients. However, the patients are not being discounted as the patient still gets the standard of care of surgery and radiotherapy. The CLTX CAR-T is just an added bonus to the standard of care. I've been involved with Phase 1/2 studies and it is not uncommon for these patients to gain access to CLTX CAR-T on a compassionate basis if there is some result that the treatment works. So if they were enrolled into Cohort 1 and if later down the track, Cohort 3 or 4 dosing treatments actually produced efficacy results, then they might be able to receive those dosing treatments.
It is all about extending patient prognosis for more opportunities. The more time they get, the more therapies they will be able to get access to and the higher chances of survivability.
CHM Price at posting:
14.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)